Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN 7 versus AMINOSYN II 15 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN 7 versus AMINOSYN II 15 IN PLASTIC CONTAINER.
AMINOSYN 7% vs AMINOSYN II 15% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminosyn 7% provides a mixture of essential and nonessential amino acids, serving as substrates for protein synthesis, thereby supporting nitrogen balance and tissue repair. It acts as a source of caloric nitrogen in parenteral nutrition.
Provides essential amino acids for protein synthesis, serving as substrates for nitrogen balance and tissue repair.
Intravenous: 500 mL to 2 L of 7% solution (35-140 g amino acids) per day by central or peripheral infusion, adjusted based on metabolic needs and nitrogen balance, usually infused at a rate not exceeding 0.1 g/kg/hour.
Intravenous infusion: 1.0 to 2.0 g amino acids/kg/day, maximum 125 mL/hour (3 g amino acids/kg/day).
None Documented
None Documented
Not applicable as a single entity; amino acids are utilized rapidly for protein synthesis and energy. Plasma amino acid levels decline with a terminal half-life of approximately 10-20 minutes post-infusion, reflecting rapid tissue uptake.
Amino acids: rapid clearance, half-life 0.5-2 hours depending on individual and metabolic state. Clinical context: continuous infusion maintains steady state.
Primarily renal elimination of infused amino acids as metabolic byproducts (urea, ammonia) and a small fraction of unchanged amino acids. Renal excretion accounts for >90% of elimination; negligible biliary/fecal.
Renal: amino acids are filtered and reabsorbed; excess nitrogen is excreted as urea in urine. <5% fecal.
Category C
Category C
Amino Acid Solution
Amino Acid Solution